T1	Participants 284 398	patients with metastatic breast cancer, where the alternate crossover monotherapy (GD→C or CD→G) was predetermined
T2	Participants 868 995	Despite over-accrual of 475 patients, the trial matured with only 324 of 385 planned TtP events due to patient discontinuations
